SCHEMBL2591029

SCHEMBL2591029

Nc1nccc(Oc2cc(F)c([N+](=O)[O-])cc2F)c1I

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 7/20 0.39
KDR P35968 4/20 0.39
HSPB1 P04792 4/20 0.38
MAPT P10636 3/20 0.37
ALDH1A1 P00352 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
PKM P14618 1/20 0.37
IDO1 P14902 1/20 0.37
RECQL P46063 1/20 0.37
TDO2 P48775 1/20 0.37
BLM P54132 1/20 0.37
CASP6 P55212 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1137074 0.82 HSPB1 (0.49) METKDRHSPB1MAPTALDH1A1
SCHEMBL30495857 0.82 HSPB1 (0.49) METKDRHSPB1MAPTALDH1A1
SCHEMBL2591537 0.80 MET (0.41) METKDR
SCHEMBL31007140 0.79 HSPB1 (0.36) METKDRHSPB1MAPTALDH1A1
SCHEMBL11933609 0.78 LMNA (0.39) METKDRMAPTALDH1A1TDP1
SCHEMBL22750267 0.75 PDGFRA (0.36) METKDRHSPB1MAPTALDH1A1
SCHEMBL29453849 0.75 PDGFRA (0.36) METKDRHSPB1MAPTALDH1A1
SCHEMBL10012916 0.74 L3MBTL1 (0.32) METHSPB1MAPTALDH1A1TDP1
SCHEMBL25362099 0.74 MET (0.48) METKDR
SCHEMBL2591352 0.74 MET (0.45) METKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569319-B2 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities Deciphera Pharmaceuticals, LLS (US) 2013-10-29 US disclosed
EP-2563773-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES Deciphera Pharmaceuticals, LLC (US) 2013-03-06 EP disclosed
US-20120172382-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC. (US) 2012-07-05 US disclosed
WO-2011139891-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES DECIPHERA PHARMACEUTICALS, LLC (US) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172382-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES MKI67, TYMP, CCNA1 MET 2197/4885KDR 2384/4885HSPB1 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.